The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Unidentified Participant - - Analyst
: This is Destiny on for Jeff. I'd like to start with face pain, if we could. I know that you had those two patients treated earlier this month, so
congratulations on that. I'm wondering if we should expect any more procedures prior to year-end. I know we're getting into the thick of the
holidays. So I'm just curious.
Question: Unidentified Participant - - Analyst
: Okay. Great. And I know historically, you had said that with this type of procedure, they could be stacked. So the treating physicians could
do more. I'm wondering, first of all, were these procedures back-to-back, maybe even not -- maybe if not on the hour, but in terms of the
days. And then based on what you heard just from those two, do you still feel like that's something that is feasible or attainable?
Question: Unidentified Participant - - Analyst
: Okay. Great. And I know you mentioned a strategic partner here. At what point do you feel like you would just go forward and do it yourself?
Question: Unidentified Participant - - Analyst
: Okay. Okay. And then just a couple on drug delivery, if I may. I'm wondering if there will be more orders from this large pharma player. And
I'm not sure how much visibility you have there, but are they going to do additional testing? Is there the opportunity to expand a bit? What
are you seeing there?
Question: Unidentified Participant - - Analyst
: Okay. Got it. And then for epilepsy, I missed what you said about the registry. What is the timing on getting that established and opened?
Question: Unidentified Participant - - Analyst
: Okay. Great. And then last one for me. I know you've mentioned raising patient awareness. And I'm wondering if you've kind of implemented
any strategies or initiatives there that we could -- that could maybe help with awareness in 2026, like another Clara story, if you will.
Question: Unidentified Participant - - Analyst
: Got it. Okay. I appreciate you taking the questions and looking forward to seeing you at JPMorgan.
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Dave, I was wondering if you could expand on the distribution agreement that you have with Zimmer Biomet. I mean, I know you said it has
expanded, but can you provide a little more color on what that includes? And then just on the lower back pain, you said you advanced the
development of that product. Can you talk about what that -- the development program looks like for lower back pain? And then I'll hop
back in with one other question.
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay. So just to be clear, right now, the OneRF for trigeminal nerve ablation is not part of the Zimmer agreement and as well as the lower
back pain, it sounds like you're speaking to strategic about that. It doesn't mean Zimmer Biomet wouldn't be one of the strategics, but you're
having discussions with other strategics for those 2 programs, correct?
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay. Great. And then my last question is on reimbursement, the reimbursement landscape and the challenges that are always present
when an emerging growth company comes to market with new technologies. Maybe just talk about a little bit of how you're navigating that?
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay. Great. Appreciate it.
| 
